Gilead Sciences has announced a $7.8 billion payment to take full control of a promising multiple myeloma therapy, expanding its oncology portfolio.

Gilead Sciences has announced its acquisition of Arcellx in a deal valued at up to $7.8 billion.

Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its portfolio in the biotechnology sector.

Barclays has adopted a neutral stance on Gilead Sciences, acknowledging its strategic refocus but maintaining a cautious outlook.

Gilead Sciences announced its plan to acquire cancer drug developer Arcellx in a deal valued at up to $7.8 billion, as pharmaceutical groups continue to acquire smaller biotech firms.

Analysts are sharing their opinions and insights on Gilead Sciences (GILD) following its recent earnings report.